A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs AT 7519 (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 19 Jun 2013 Novartis added as associations and lead trial centre as reported by ClinicalTrials.gov.